AMA supports FDA’s changes to prescription opioids labels

| 3 Min Read

Statement attributable to:
Barbara L. McAneny, M.D.
President, American Medical Association

“With overdoses and deaths continuing to plague communities across the country, the AMA welcomes the FDA’s decision to include tapering guidance on the labels of prescription opioids. This patient-centric approach will encourage discussions between patients and physicians on whether a decrease in dose or discontinuation of the opioid is the best approach. If so, the patient and physicians should discuss how to safely decrease dosages. The FDA notes that there is no standard tapering schedule suitable for all patients. The right approach depends on conversations between patients and physicians, including a decision to maintain the patient on a current dose if the benefits outweigh the risks.  

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Hands hold a smartphone

More than 80% of physicians use AI professionally: AMA survey

| 4 Min Read
People in a group with stacked hands

Embedding physician well-being into system strategy

| 8 Min Read
Smiling woman works at a laptop

Medicare patients get virtual access to diabetes prevention

| 3 Min Read
Operating room corridor

A more accurate Medicare Advantage provider directory on the way

| 4 Min Read